Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, Litzow MR, Tallman MS, Shanafelt TD, Kay NE. Wang XV, et al. Among authors: lesnick ce. Blood. 2021 Dec 30;138(26):2810-2827. doi: 10.1182/blood.2020010146. Blood. 2021. PMID: 34407545 Free PMC article. Clinical Trial.
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
Ding W, Shanafelt TD, Lesnick CE, Erlichman C, Leis JF, Secreto C, Sassoon TR, Call TG, Bowen DA, Conte M, Kumar S, Kay NE. Ding W, et al. Among authors: lesnick ce. Br J Haematol. 2014 Jan;164(1):146-50. doi: 10.1111/bjh.12564. Epub 2013 Sep 20. Br J Haematol. 2014. PMID: 24111951 Free PMC article. No abstract available.
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, Lesnick C, Tschumper R, Jelinek D, Kay NE, Ding W. Larsen JT, et al. Am J Hematol. 2017 Aug;92(8):759-763. doi: 10.1002/ajh.24762. Epub 2017 Jun 1. Am J Hematol. 2017. PMID: 28402581 Free PMC article. Clinical Trial.
Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL).
Shanafelt TD, Kay NE, Parikh SA, Achenbach SJ, Lesnick CE, Hanson CA, Kleinstern G, Olson JE, Norman AD, Rabe KG, Schwager SM, Call TG, Slager SL. Shanafelt TD, et al. Among authors: lesnick ce. Leukemia. 2021 Jan;35(1):239-244. doi: 10.1038/s41375-020-0799-8. Epub 2020 Mar 18. Leukemia. 2021. PMID: 32203143 Free PMC article. No abstract available.
24 results